{"id":1735,"date":"2013-01-06T09:46:37","date_gmt":"2013-01-06T00:46:37","guid":{"rendered":"\/sawamura\/?p=1735"},"modified":"2021-03-08T13:35:09","modified_gmt":"2021-03-08T04:35:09","slug":"avastine","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/sawamura\/glioma\/avastine\/","title":{"rendered":"\u30a2\u30d0\u30b9\u30c1\u30f3\uff08\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\uff09"},"content":{"rendered":"<h5><span style=\"color: #ff0000;\">\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u85ac\u30d9\u30d0\u30b7\u30ba\u30de\u30d6<\/span><span style=\"font-weight: normal;\"> \u00a0<strong>bevacizumab<\/strong><\/span><\/h5>\n<ul>\n<li>\u8133\u5185\u90e8\u304b\u3089\u3067\u308b<span style=\"color: #000080;\"><strong>\u30b0\u30ea\u30aa\u30fc\u30de\uff08\u60aa\u6027\u795e\u7d4c\u81a0\u816b\uff09\u306e\u6cbb\u7642<\/strong><\/span>\u306b\u4f7f\u308f\u308c\u308b\u85ac\u3067\u3059<\/li>\n<li>\u81a0\u82bd\u816b\u3068\u304b\u9000\u5f62\u6210\u6027\u661f\u7d30\u80de\u816b\u3068\u304b\u3044\u308d\u3044\u308d\u306a\u60aa\u6027\u8133\u816b\u760d\u306b\u6709\u52b9\u306a\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n<li>\u30b0\u30ea\u30aa\u30fc\u30de\u306e<strong><span style=\"color: #ff0000;\">\u816b\u760d\u8840\u7ba1\u304c\u5897\u3048\u308b\u3053\u3068\u3092\u59a8\u5bb3\u3059\u308b\u85ac<\/span><\/strong>\u3067\uff0c\u8840\u6db2\u306e\u6d41\u308c\u3092\u6b62\u3081\u3066\uff0c\u816b\u760d\u304c\u5927\u304d\u304f\u306a\u3089\u306a\u3044\u3088\u3046\u306b\u3057\u307e\u3059<\/li>\n<li>\u816b\u760d\u7d30\u80de\u305d\u306e\u3082\u306e\u3092\u6bba\u3059\u529b\u306f\u3042\u308a\u307e\u305b\u3093<\/li>\n<li>\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u6295\u4e0e\u3059\u308b\u3068\u3059\u3050\u306b\u6570\u65e5\u4ee5\u5185\u306b\uff0c\u816b\u760d\u304c\u3068\u3066\u3082\u5c0f\u3055\u304f\u306a\u3063\u3066\u898b\u3048\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n<li>\u304a\u533b\u8005\u3055\u3093\u3082\u60a3\u8005\u3055\u3093\u3082\u559c\u3076\u306e\u3067\u3059\u304c\uff0c\u3053\u308c\u306f<span style=\"color: #ff0000;\"><strong>\u898b\u305b\u304b\u3051\u52b9\u679c<\/strong><\/span>\u3067\u3042\u3063\u3066\uff0c\u816b\u760d\u304c\u5c0f\u3055\u304f\u306a\u3063\u3066\u3044\u308b\u308f\u3051\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/li>\n<li><strong><span style=\"color: #ff0000;\">\u30a2\u30d0\u30b9\u30c1\u30f3\u5358\u72ec\u3067\u306f\u816b\u760d\u304c\u6cbb\u308b\u3068\u3044\u3046\u3053\u3068\u306f\u306a\u3044\u3068\u8003\u3048\u305f\u65b9\u304c\u3044\u3044\u3067\u3057\u3087\u3046<\/span><\/strong><\/li>\n<li><span style=\"color: #000080;\"><strong>\u521d\u767a\u306e\u81a0\u82bd\u816b\u306b\u4f7f\u7528\u3057\u3066\u3082\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\uff08\u5ef6\u547d\uff09\u306f\u3067\u304d\u307e\u305b\u3093<\/strong><\/span><\/li>\n<li><span style=\"color: #000080;\"><strong>2018\u5e74\u6642\u70b9\u3067\uff0c\u521d\u767a\u81a0\u82bd\u816b\u306e\u521d\u671f\u6cbb\u7642\u306b\u306f\u4f7f\u7528\u3059\u308b\u3079\u304d\u3067\u306f\u306a\u3044<\/strong><\/span>\u3068\u3055\u308c\u3066\u3044\u307e\u3059<\/li>\n<li>2018\u5e74\u6642\u70b9\u3067\uff0c<span style=\"color: #000080;\"><strong>\u518d\u767a\u306e\u661f\u7d30\u80de\u816b\u3068\u9000\u5f62\u6210\u6027\u661f\u7d30\u80de\u816b\u306b\u3082\u7121\u52b9<\/strong><\/span>\u3060\u3068\u3055\u308c\u3066\u3044\u307e\u3059<\/li>\n<li>\u3067\u3082\uff0c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u3092\u53d7\u3051\u3066\u6025\u901f\u306b\u5897\u5927\u3057\u3066\u3044\u308b\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u3092\uff0c\u4e00\u6642\u7684\u306b\u3082\u5c0f\u3055\u304f\u3059\u308b\u52b9\u679c\u306f\u8a8d\u3081\u3089\u308c\u3066\u3044\u307e\u3059<\/li>\n<li>\u75c7\u72b6\u304c\u5f37\u304f\u3066\u304b\u306a\u308a\u5927\u304d\u304f\u30b9\u30c6\u30ed\u30a4\u30c9\u306b\u62b5\u6297\u6027\u306a\u3082\u306e\u3067\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u8010\u3048\u3089\u308c\u306a\u3044\u3068\u8003\u3048\u3089\u308c\u308b\u521d\u767a\u81a0\u82bd\u816b\u306b\u306f\u4f7f\u7528\u3057\u3066\u3082\u826f\u3044\u306e\u304b\u3082\u3057\u308c\u307e\u305b\u3093<\/li>\n<li>corticosteroid-sparing agent\u3068\u8a00\u308f\u308c\uff0c\u8133\u6d6e\u816b\u304c\u5f37\u3044\u4f8b\u3067\u305d\u308c\u3092\u6539\u5584\u3059\u308b\u4f5c\u7528\u304c\u3042\u308a\u307e\u3059<\/li>\n<li>\u4e00\u822c\u7684\u306b\u306f\uff0c\u624b\u8853\u6458\u51fa\u3057\u3066\uff0c\u653e\u5c04\u7dda\u30fb\u30c6\u30e2\u30c0\u30fc\u30eb\u30fb\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f75\u7528\u3059\u308b\u65b9\u6cd5\u3067\u3059<\/li>\n<li><span style=\"color: #000080;\"><strong>\u9000\u9662\u3057\u3066\u304b\u3089\u3082\u5916\u6765\u3067\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u4f75\u7528<\/strong><\/span>\u3057\u3066\u4f7f\u3046\u3053\u3068\u3082\u3042\u308a\u307e\u3059<\/li>\n<li><span style=\"color: #000080;\"><strong>\u518d\u767a\u3057\u305f\u6642<\/strong><\/span>\u306b\u3082\u6025\u6fc0\u306a\u5897\u60aa\u3092\u4e00\u6642\u7684\u306b\u6291\u5236\u3059\u308b\u306e\u306b\u4f7f\u3044\u307e\u3059<\/li>\n<li>\u81a0\u82bd\u816b\u306e\u6cbb\u7642\u5f8c\u518d\u71c3\u5897\u60aa progression\u307e\u3067\u306e\u671f\u9593\u3092\u5ef6\u9577\u3067\u304d\u308b\u3068\u3055\u308c\u3066\u3044\u307e\u3059\u304c\uff0c\u53cd\u8ad6\u3082\u3042\u308a\u307e\u3059<\/li>\n<li><span style=\"color: #ff0000;\"><strong><a title=\"\u653e\u5c04\u7dda\u8133\u58ca\u6b7b radiation necrosis\" href=\"\/sawamura\/braintumors\/radiationnecrosis\/\"><span style=\"color: #ff0000;\">\u653e\u5c04\u7dda\u58ca\u6b7b radiation necrosis <\/span><\/a><\/strong><strong><span style=\"color: #ff0000;\">\u306e\u6cbb\u7642<\/span>\u306b\u6709\u52b9\u6027\u304c\u3042\u308a\u307e\u3059<\/strong><\/span><\/li>\n<li><span style=\"color: #000080;\"><strong><a style=\"color: #000080;\" href=\"\/sawamura\/glioma\/pseudoprogression\/\">\u30b9\u30fc\u30c9\u30fb\u30d7\u30ed\u30b0\u30ec\u30c3\u30b7\u30e7\u30f3<\/a>\u306e\u6cbb\u7642\u306b\u6709\u52b9\u306a\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/strong><\/span><\/li>\n<li>\u3055\u307e\u3056\u307e\u306a\u60aa\u6027\u795e\u7d4c\u81a0\u816b\uff08\u30b0\u30ec\u30fc\u30c9\uff13\u3068\u30b0\u30ec\u30fc\u30c9\uff14\uff09\u306e\u521d\u767a\u6642 (first line therapy)\u00a0\u306b\u3082\u4f7f\u7528\u3055\u308c\u307e\u3059\u304c\uff0c\u6279\u5224\u7684\u610f\u898b\u3082\u591a\u3044\u3067\u3059<\/li>\n<li><span style=\"color: #000000;\"><a title=\"\u8996\u795e\u7d4c\u81a0\u816b\uff0c\u8996\u8def\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b optic pathway glioma\" href=\"\/sawamura\/pediattumor\/opticpathwaypil\/\"><span style=\"color: #000080;\">\u8996\u795e\u7d4c\u81a0\u816b<\/span><\/a>\u3084<span style=\"color: #000080;\"><a title=\"\u795e\u7d4c\u7dda\u7dad\u816b\u75c7 NF-1, NF-2\" href=\"\/sawamura\/braintumors\/neurofibromatosis\/\">\u795e\u7d4c\u7dda\u7dad\u816b\u75c7\uff12\u578b<\/a><\/span>\u306a\u3069\u4ed6\u306e\u816b\u760d\u306b\u3082\u5fdc\u7528\u3055\u308c\u3066\u3044\u307e\u3059<\/span><\/li>\n<li><span style=\"color: #000080;\"><strong>\u526f\u4f5c\u7528\u306f\u5c11\u306a\u3044<\/strong><\/span>\u5236\u304c\u3093\u5264\u3068\u3044\u3048\u308b\u3067\u3057\u3087\u3046<\/li>\n<li><strong><span style=\"color: #ff0000;\">\u9ad8\u984d<\/span><\/strong>\u306a\u6cbb\u7642\u85ac\u3067\u3059<\/li>\n<li>\u5165\u9662\u3067\u3082\u5916\u6765\u3067\u3082\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u3046\u3068\u9ad8\u984d\u533b\u7642\u306b\u306a\u308a\u307e\u3059\u304b\u3089\uff0c\u81ea\u5df1\u8ca0\u62c5\u9650\u5ea6\u984d\u307e\u3067\u306e\u652f\u6255\u3044\u3068\u306a\u308a\u307e\u3059<\/li>\n<\/ul>\n<h5>\u306a\u305c\u60aa\u6027\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u52b9\u304f\u306e\u304b<\/h5>\n<ul>\n<li>\u3053\u306e20\u5e74\u3067\uff0c\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u304c\u6210\u9577\u3059\u308b\u305f\u3081\u306b\u5fc5\u7528\u3068\u3059\u308b\u5206\u5b50\uff08\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u306a\u3069\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u3084\u53d7\u5bb9\u4f53\uff09\u304c\u305f\u304f\u3055\u3093\u77e5\u3089\u308c\u3066\u304d\u307e\u3057\u305f<\/li>\n<li>\u304b\u3064\u3066\u306f\u5b9f\u9a13\u5ba4\u306e\u4e2d\u3067\u306e\u304a\u8a71\u3067\u3057\u305f\u304c\uff0c\u73fe\u5728\u3067\u306f\u305f\u304f\u3055\u3093\u306e\u85ac\uff08<span style=\"color: #000080;\"><strong>\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u85ac<\/strong><\/span>\uff09\u304c\u60a3\u8005\u3055\u3093\u306b\u4f7f\u7528\u3055\u308c\u3066\u3044\u307e\u3059<\/li>\n<li><span style=\"color: #000000;\">\u5546\u54c1\u540d\u30a2\u30d0\u30b9\u30c1\u30f3 Avastine\uff08\u6b63\u5f0f\u306b\u306f\u30d9\u30d0\u30b7\u30ba\u30de\u30d6 bevacizumab\uff09\u306f\uff0c<span style=\"color: #ff0000;\"><strong>VEGF\u3068\u3044\u3046\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u5897\u6b96\u56e0\u5b50\u306e\u50cd\u304d\u3092\u6291\u3048\u308b\u5358\u30af\u30ed\u30fc\u30f3\u6297\u4f53<\/strong><\/span>\u3067\u901a\u5e38\u306e\u6297\u304c\u3093\u5264\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/span><\/li>\n<li><span style=\"color: #000000;\">VEGF\u00a0(vascular endothelial growth factor)\u3068\u3044\u3046\u8840\u7ba1\u5897\u6b96\u56e0\u5b50\u306b\u304f\u3063\u3064\u3044\u3066\uff0c\u305d\u306e\u4f5c\u7528\u3092\u6291\u5236\u3057\u307e\u3059<\/span><\/li>\n<li><span style=\"color: #000000;\">\u81a0\u82bd\u816b\u306f\u305f\u304f\u3055\u3093\u306eVEGF\u3092\u7523\u751f\u3059\u308b\u306e\u3067\uff0c\u8840\u7ba1\u5897\u6b96\u304c\u65fa\u76db\u3067\uff0c\u8133\u306e\u8840\u7ba1\u304b\u3089\u306e\u8c4a\u5bcc\u306a\u8840\u6d41\u3092\u5f15\u304d\u8fbc\u3093\u3067\uff0c\u6025\u901f\u306b\u816b\u760d\u7d30\u80de\u304c\u5897\u3048\u3066\u3044\u304f\u60aa\u6027\u816b\u760d\u3067\u3059<\/span><\/li>\n<li><span style=\"color: #000000;\">\u5927\u4e8b\u306a\u3053\u3068\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306e\u8840\u7ba1\u5897\u6b96\u901f\u5ea6\u3092\u9045\u304f\u3059\u308b\u4f5c\u7528\u304c\u3042\u308b\u306e\u3067\u3059\u304c\uff0c\u816b\u760d\u7d30\u80de\u3092\u6bba\u3059\u4f5c\u7528 cytocidal effect \u304c\u306a\u3044\u3053\u3068\u3067\u3059<\/span><\/li>\n<li><span style=\"color: #000000;\">\u3067\u3059\u304b\u3089\uff0c<span style=\"color: #000080;\"><strong>\u3053\u306e\u85ac\u5264\u5358\u72ec\u3067\u816b\u760d\u304c\u6cbb\u308b\u3068\u3044\u3046\u671f\u5f85\u306f\u6975\u3081\u3066\u4f4e\u3044<\/strong><\/span>\u3082\u306e\u3067\u3059<\/span><\/li>\n<li>\u591a\u304f\u306e\u5834\u5408\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u3067\u816b\u760d\u304c\u5c0f\u3055\u304f\u306a\u3063\u305f\u3088\u3046\u306b\u898b\u3048\u308b\u306e\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u304c\u8133\u8840\u7ba1\u900f\u904e\u6027 vascular\u00a0permeability of blood-brain barrier\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u306e\u3067\uff0c\u8133\u6d6e\u816b\u304c\u8efd\u6e1b\u3057\u305f\u308a\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u9020\u5f71\u5264\u304c\u816b\u760d\u306b\u5165\u308a\u306b\u304f\u304f\u306a\u3063\u305f\u308a\u3059\u308b\u305f\u3081\u3067\u3059<\/li>\n<li>IDH-1\u5909\u7570\u306e\u306a\u3044<span style=\"color: #000080;\"><strong>\u81a0\u82bd\u816b IDH wild-type<\/strong><\/span> \u306b\u306f1\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u521d\u671f\u6cbb\u7642\u3067\u4f75\u7528\u3059\u308b\u3068\u751f\u5b58\u671f\u9593\u5ef6\u9577\u304c\u3042\u308b\u304b\u3082\u3057\u308c\u307e\u305b\u3093<\/li>\n<\/ul>\n<h4>\u4f7f\u7528\u91cf\u306e\u304a\u3088\u305d\u306e\u76ee\u5b89<\/h4>\n<p><span style=\"color: #000080;\"><strong>\u2606 \u521d\u671f\u6cbb\u7642\uff08\u521d\u767a\u6642\uff09<\/strong><\/span><\/p>\n<h5>\u521d\u671f\u6cbb\u7642\u3067\u653e\u5c04\u7dda\u6cbb\u7642\u3068\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u4f75\u7528\u3059\u308b\u6642\uff08\u653e\u5c04\u7dda \uff16\u9031\u9593\uff09<br \/>\n1\u56de10mg\/kg\uff08\u4f53\u91cd\uff09\u3092<span style=\"color: #ff0000;\">2\u9031\u9593\u9593\u9694<\/span>\u3067\u70b9\u6ef4\u9759\u8108\u5185\u6ce8\u5c04<\/h5>\n<h5>\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u306b\u3067\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u4f75\u7528\u3059\u308b\u6642\uff08\u30c6\u30e2\u30c0\u30fc\u30eb 6\u30b3\u30fc\u30b9\uff09<br \/>\n1\u56de10mg\/kg\uff08\u4f53\u91cd\uff09\u3092<span style=\"color: #ff0000;\">2\u9031\u9593\u9593\u9694<\/span>\u3067\u70b9\u6ef4\u9759\u8108\u5185\u6ce8\u5c04<\/h5>\n<h5>\u305d\u306e\u5f8c\u306e\u7dad\u6301\u7642\u6cd5\u3067\u30a2\u30d0\u30b9\u30c1\u30f3\u5358\u72ec\u3067\u4f7f\u3046\u6642<br \/>\n1\u56de15mg\/kg\uff08\u4f53\u91cd\uff09\u3092<span style=\"color: #ff0000;\">3\u9031\u9593\u9593\u9694<\/span>\u3067\u70b9\u6ef4\u9759\u8108\u5185\u6ce8\u5c04<\/h5>\n<p><span style=\"color: #000080;\"><strong>\u2606 \u518d\u767a\u6642<\/strong><\/span><\/p>\n<h5>\u518d\u767a\u6642\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u5358\u72ec\u3067\u4f7f\u3046\u6642<br \/>\n1\u56de10mg\/kg\uff08\u4f53\u91cd\uff09\u3092<span style=\"color: #ff0000;\">2\u9031\u9593\u9593\u9694<\/span>\u3067\u70b9\u6ef4\u9759\u8108\u5185\u6ce8\u5c04<\/h5>\n<h5>\u518d\u767a\u6642\u306b\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u4f75\u7528\u3059\u308b\u6642<br \/>\n1\u56de10mg\/kg\uff08\u4f53\u91cd\uff09\u3092<span style=\"color: #ff0000;\">2\u9031\u9593\u9593\u9694<\/span>\u3067\u70b9\u6ef4\u9759\u8108\u5185\u6ce8\u5c04<\/h5>\n<h4>\u526f\u4f5c\u7528\uff08\u6709\u5bb3\u4e8b\u8c61\uff09<\/h4>\n<ul>\n<li>\u983b\u5ea6\u306f\u4f4e\u3044\u306a\u304c\u3089\u3082\uff0c\u751f\u3058\u308b\u3068\u91cd\u3044\u526f\u4f5c\u7528\u304c\u3042\u308a\u307e\u3059\u3002<\/li>\n<li>\u80ba\u51fa\u8840\uff08\u5580\u8840\uff09\uff0c\u8840\u6813\u585e\u6813\u75c7\uff08\u9759\u8108\u8840\u6813\uff09\uff0c\u6d88\u5316\u7ba1\u51fa\u8840\uff08\u7a7f\u5b54\uff09\uff0c\u5275\u50b7\u6cbb\u7642\u306e\u9045\u5ef6\uff0c\u8840\u5727\u4e0a\u6607\uff08\u9ad8\u8840\u5727\u6027\u8133\u75c7\uff0c\u9ad8\u8840\u5727\u6027\u30af\u30ea\u30fc\u30bc\uff09\uff0c\u53ef\u9006\u6027\u5f8c\u767d\u8cea\u8133\u75c7\u75c7\u5019\u7fa4\uff0c\u86cb\u767d\u5c3f\u306a\u3069\u304c\u3042\u3052\u3089\u308c\u307e\u3059\u3002<\/li>\n<li>\u9577\u671f\u6295\u4e0e\u3067\u306f\u9ad8\u8840\u5727\u3068\u86cb\u767d\u5c3f\u306e\u983b\u5ea6\u304c\u304b\u306a\u308a\u9ad8\u304f\u306a\u308a\u307e\u3059\u3002<\/li>\n<li><span style=\"color: #000080;\"><strong>\u8133\u816b\u760d\u7279\u6709\u306e\u3082\u306e\u3068\u3057\u3066\u306f\uff0cdehiscence\u3068\u3044\u308f\u308c\u308b\u958b\u982d\u90e8\u4f4d\u3067\u306e\u5275\u50b7\u6cbb\u7652\u9045\u5ef6\uff0c\u8133\u816b\u760d\u5185\u51fa\u8840\uff08\u8133\u51fa\u8840\uff09\u306a\u3069\u304c\u6700\u3082\u6ce8\u610f\u3059\u308b\u3079\u304d\u526f\u4f5c\u7528<\/strong><\/span>\u3067\u3059\u3002<\/li>\n<li>\u958b\u982d\u624b\u8853\u304b\u3089\u65e5\u304c\u6d45\u304f\uff0c\u50b7\u304c\u5341\u5206\u6cbb\u3063\u3066\u3044\u306a\u3044\u6642\u671f\uff084\u9031\u9593\u4ee5\u5185\u307e\u3067\u304f\u3089\u3044\uff09\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3059\u308b\u3068\u50b7\u304c\u958b\u3044\u3066\u3057\u307e\u3046\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002<\/li>\n<li>\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u306f\u7570\u306a\u308a\uff0c\u526f\u4f5c\u7528\u3068\u3057\u3066\u306e\u9aa8\u9ac4\u6291\u5236\u304c\u8efd\u3044\u306e\u3067\uff0c\u30c6\u30e2\u30c0\u30fc\u30eb\u3068\u306e\u4f75\u7528\u304c\u53ef\u80fd\u3067\u3059\u3002\u3067\u3082\u767d\u8840\u7403\u6570\u306b\u306f\u8981\u6ce8\u610f\u3067\u3059\u3002<\/li>\n<\/ul>\n<h5>2014\u5e74\u306b\u767a\u8868\u3055\u308c\u305f\u4ee5\u4e0b\u306e\uff12\u3064\u306e\u5927\u304d\u306a\u81e8\u5e8a\u7814\u7a76\u3067\uff0c\u3082\u3063\u3068\u3082\u6ce8\u76ee\u3055\u308c\u305f\u81a0\u82bd\u816b\u3078\u306e\u52b9\u679c\u304c\u5426\u5b9a\u3055\u308c\u3066\u3057\u307e\u3044\u307e\u3057\u305f<\/h5>\n<h4>\u30d0\u30a4\u30aa\u30b7\u30df\u30e9\u30fc<\/h4>\n<p>Singh GK: Safety and efficacy of bevacizumab biosimilar in recurrent\/ progressive glioblastoma. eCancer 2021<br \/>\n\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u6297\u4f53\u306a\u306e\u3067\u539f\u5247\u3068\u3057\u3066\u5f8c\u767a\u54c1 generic\u304c\u3067\u304d\u307e\u305b\u3093\u3002\u5148\u767a\u3092innovator\u3068\u3044\u3044\u307e\u3059\u3002\u5f8c\u767a\u54c1\u306f\uff0c\u5fc5\u305a\u3057\u3082\u540c\u3058\u88fd\u5264\u3067\u306f\u306a\u3044\u6297\u4f53 biosimilar \u3068\u306a\u308a\u307e\u3059\u304b\u3089\uff0c\u305d\u306e\u6709\u52b9\u6027\u3092\u8a3c\u660e\u3059\u308b\u3053\u3068\u306f\u3068\u3066\u3082\u96e3\u3057\u3044\u3082\u306e\u3067\u3057\u305f\u30022021\u5e74\u306b\u30a4\u30f3\u30c9\u3067\u306e\u81e8\u5e8a\u8a66\u9a13\u3067\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u5f8c\u767a\u54c1 biosimilar\u304cinnovator\u3068\u540c\u69d8\u306e\u52b9\u679c\u304c\u3042\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002\u753b\u671f\u7684\u306a\u3053\u3068\u3067\u3059\u3002<\/p>\n<p>2021\u5e74\u4e2d\u56fd\u3067\u3082\u30a2\u30d0\u30b9\u30c1\u30f3\u306ebiosimilar\u304c\u8a8d\u53ef\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<h4>\u3073\u307e\u3093\u6027\u661f\u7d30\u80de\u816b\u3068\u9000\u5f62\u6210\u6027\u661f\u7d30\u80de\u816b\u306e<span style=\"color: #ff0000;\"><strong>\u518d\u767a\u306b\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u7121\u52b9<\/strong><\/span><\/h4>\n<p>van den Bent MJ: Bevacizumab\u00a0and\u00a0temozolomide\u00a0in\u00a0patients\u00a0with\u00a0first\u00a0recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.\u00a0 Lancet Oncol.\u00a02018<br \/>\n\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u9020\u5f71\u3055\u308c\u308b\u518d\u767a\u661f\u7d30\u80de\u7cfb\u816b\u760d\u306b\u5bfe\u3057\u3066\uff0c\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u5358\u72ec\u3042\u308b\u3044\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u4f75\u7528\u306e\u8a66\u9a13\u304c\u306a\u3055\u308c\u307e\u3057\u305f\u3002115\u4f8b\u306e\u7121\u4f5c\u70ba\u8a66\u9a13\u3067\u3059\u3002PFS\uff0cOS\uff0c\uff0cQOL\uff0c\u753b\u50cf\u4e0a\u306e\u52b9\u679c\u3067\uff0c\u5168\u3066\u304c\u9670\u6027\u306e\u7d50\u679c\u3067\u3059\u3002\u526f\u4f5c\u7528\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3057\u305f\u307b\u3046\u304c\u591a\u304b\u3063\u305f\u3068\u3042\u308a\u307e\u3059\u3002IDH\u306e\u5909\u7570\u306e\u6709\u7121\u306b\u3082\u95a2\u4fc2\u304c\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<div>\n<h4><span style=\"color: #ff0000;\"><strong>\u00a0\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u81a0\u82bd\u816b\u306e\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3057\u306a\u3044<\/strong><span style=\"color: #000000;\">\uff08\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13\uff09<\/span><\/span><\/h4>\n<p>Gilbert MR, et al.: A randomized trial of bevacizmab for newly diagnosed glioblastoma.\u00a0 N Engl J Med 370: 699-708, 2014<br \/>\n<span style=\"color: #ff0000;\"><strong>AVAglio \u30a2\u30d0\u30b0\u30ea\u30aa\u00a0<\/strong><\/span>\u3068\u3044\u3046\u56fd\u969b\u5171\u540c\u7814\u7a76\u3067\u3059\u3002Stupp\u30ec\u30b8\u30e1\u30f3\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\uff08\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\uff09\u3092\u4e0a\u4e57\u305b\u3059\u308b\u4f75\u7528\u6cbb\u7642\u3067\u3059\u300260\u30b0\u30ec\u30a4\uff081\u65e5\u3042\u305f\u308a2Gy\u7167\u5c04\u30926\u9031\u9593\uff09\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u4e2d\u306b\u3001\u30c6\u30e2\u30c0\u30fc\u30eb\uff081\u65e5\u3042\u305f\u308a75mg\/m2\uff09\u9023\u65e5\u6295\u4e0e\u3001<strong><span style=\"color: #000080;\">\u30a2\u30d0\u30b9\u30c1\u30f3\u30922\u9031\u9593\u9593\u9694\u306710 mg\/kg\u6295\u4e0e\u3057\u307e\u3057\u305f\u3002\u305d\u306e\u5f8c\u306f\uff0c\uff13\u9031\u9593\u9694\u3067\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u309212\u30b5\u30a4\u30af\u30eb\u7d99\u7d9a\u3057\u307e\u3057\u305f<\/span>\u3002<\/strong>637\u4eba\u306e\u60a3\u8005\u3055\u3093\u304c\u6cbb\u7642\u3055\u308c\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u4f7f\u7528\u7fa4\u306e\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593 PFS\u306f10.7\u30f6\u6708\uff0c\u4f7f\u7528\u3057\u306a\u3044\u5834\u5408\u306f7.3\u30f6\u6708\u3067\u6709\u610f\u5dee\u304c\u3042\u308a\u307e\u3057\u305f\u3002\u5168\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024 OS\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u4f7f\u7528\u7fa4\u306715.7\u30f6\u6708\uff0c\u4f7f\u7528\u3057\u306a\u3044\u5834\u5408\u306f16.1\u30f6\u6708\u3067\u3042\u308a\uff0c\u3053\u308c\u306b\u306f\u6709\u610f\u306a\u5dee\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u3053\u3053\u3067\u3082<span style=\"color: #000080;\"><strong>\u75c5\u52e2\u306e\u9032\u884c\u306f\u3042\u308b\u7a0b\u5ea6\u6291\u3048\u3089\u308c\u308b\u3051\u308c\u3069\u3082\uff0c\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u306f\u5f97\u3089\u308c\u306a\u3044<\/strong><\/span>\u3068\u3044\u3046\u6700\u7d42\u6210\u7e3e\u3067\u3059\u3002\u3055\u3089\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3057\u305f\u7fa4\u3067\uff0c\u8a08\u753b\u6642\u306b\u671f\u5f85\u3057\u305f\u52b9\u679c\u306f\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\uff0c\u89b3\u5bdf\u671f\u9593\u306e\u5ef6\u9577\u3068\u3068\u3082\u306b\u75c7\u72b6\u306e\u60aa\u5316\u30fb\u751f\u5b58\u306e\u8cea QOL \u306e\u60aa\u5316\u30fb\u8a8d\u77e5\u6a5f\u80fd\u306e\u60aa\u5316\u304c\u3042\u3063\u305f\u3068\u306e\u8ffd\u8a18\u304c\u3042\u308a\u307e\u3057\u305f\u3002<span style=\"color: #000080;\"><strong>\u4f7f\u7528\u3059\u308b\u3053\u3068\u306b\u3088\u3063\u3066\uff0c\u65e9\u671f\u306e\u8a8d\u77e5\u6a5f\u80fd\u60aa\u5316\u3092\u62db\u304f<\/strong><\/span>\u53ef\u80fd\u6027\u304c\u5f37\u304f\u793a\u5506\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306b\u30b9\u30fc\u30c9\u30d7\u30ed\u30b0\u30ec\u30c3\u30b7\u30e7\u30f3\u3092\u6291\u5236\u3059\u308b\u898b\u304b\u3051\u306e\u52b9\u679c\u304c\u3042\u308b\u305f\u3081\u3067\u3042\u3063\u3066\uff0c\u771f\u306e\u6297\u816b\u760d\u52b9\u679c true effect \u3067\u306f\u306a\u3044\u3068\u3044\u3046\u8ad6\u8a55\u3082\u3042\u308a\u307e\u3059\u3002<\/p>\n<h4><span style=\"color: #ff0000;\"><strong>\u00a0\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u81a0\u82bd\u816b\u306e\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3057\u306a\u3044<\/strong><span style=\"color: #000000;\">\uff08\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13\uff09<\/span><\/span><\/h4>\n<p>Chinot OL, et al.: Bebacizmab plus radiotherapy-temozolomide for newly diagnosed gliomblastoma. N Engl J Med 370: 709-722, 2014<br \/>\n\u30e8\u30fc\u30ed\u30c3\u30d1\u304b\u3089\u306e\u3082\u306e(<span style=\"color: #ff0000;\"><strong>RTOG 0825<\/strong><\/span>)\u3067\uff0c921\u4eba\u306e\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u3092\u5bfe\u8c61\u3068\u3057\u3066\u30a2\u30d0\u30b0\u30ea\u30aa\u3068\u540c\u69d8\u306e\u8a66\u9a13\u304c\u3055\u308c\u307e\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u4f7f\u7528\u7fa4\u306e\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593 PFS\u306f10.6\u30f6\u6708\uff0c\u4f7f\u7528\u3057\u306a\u3044\u5834\u5408\u306f6.2\u30f6\u6708\u3067\u6709\u610f\u5dee\u304c\u3042\u308a\u307e\u3057\u305f\u30022\u5e74\u751f\u5b58\u5272\u5408 2-year OS\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u4f7f\u7528\u7fa4\u306733.9%\uff0c\u4f7f\u7528\u3057\u306a\u3044\u5834\u5408\u306f30.1%\u3067\u3042\u308a\uff0c\u3053\u308c\u306b\u306f\u6709\u610f\u306a\u5dee\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3057\u305f\u307b\u3046\u304cQOL\u3068PS\u306e\u7dad\u6301\u304c\u3067\u304d\u305f\u3051\u308c\u3069\u3082\uff0c\u526f\u4f5c\u7528\uff08\u6709\u5bb3\u4e8b\u8c61\uff09\u3082\u591a\u304b\u3063\u305f\u3068\u3044\u3046\u7d50\u679c\u3067\u3059\u3002<span style=\"color: #000080;\"><strong>\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3057\u3066\u3082\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u304c\u306a\u3044<\/strong><\/span>\u3068\u3044\u3046\u7d50\u8ad6\u3067\u3057\u305f\u3002<\/p>\n<\/div>\n<h4><strong>\u30a2\u30d0\u30b9\u30c1\u30f3\u7279\u6709\u306e\u753b\u50cf\u6240\u898b\u306e\u5909\u5316<\/strong><\/h4>\n<ul>\n<li>\u30b0\u30ec\u30fc\u30c93\u3084\u30b0\u30ec\u30fc\u30c94\u306e\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306f\uff0c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u75c5\u5909\u3067\u816b\u760d\u306e\u5927\u304d\u3055\u3092\u8a55\u4fa1\u3059\u308b\u3053\u3068\u304c\u591a\u3044\u3067\u3059\uff08Macdonald Criteria)<\/li>\n<li>\u30a2\u30d0\u30b9\u30c1\u30f3\u306a\u3069\u306eantiangiogenatic agent (\u8840\u7ba1\u65b0\u751f\u3092\u963b\u5bb3\u3059\u308b\u85ac\uff09\u3092\u4f7f\u7528\u3059\u308b\u3068\uff0c<span style=\"color: #000080;\"><strong>\u6295\u4e0e\u6570\u65e5\u4ee5\u5185\u306b\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u75c5\u5909\u304c\u7e2e\u5c0f<\/strong><\/span>\u3057\u3066\uff0c\u4e00\u898b\u6cbb\u7642\u304c\u3068\u3066\u3082\u6709\u52b9\u306a\u3088\u3046\u306b\u307f\u3048\u308b\u3053\u3068\u304c\u591a\u3044\u3067\u3059<\/li>\n<li>\u3053\u308c\u306fT1\u5f37\u8abf\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u50cf\u3067\u8a55\u4fa1\u3059\u308c\u3070\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u52b9\u679c\u304c\u3042\u308b\u3068\u3044\u3046\u3053\u3068\u306b\u306a\u308a\u307e\u3059\uff0c\u3082\u3061\u308d\u3093\u60aa\u3044\u73fe\u8c61\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/li>\n<li>\u3053\u308c\u306f\u8840\u6db2\u8133\u95a2\u9580\u306e\u900f\u904e\u6027\u304c\u4e0b\u304c\u3063\u3066\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u304c\u816b\u760d\u7d44\u7e54\u5185\u306b\u6f0f\u51fa\u3067\u304d\u306a\u304f\u306a\u308b\u3068\u3044\u3046<span style=\"color: #000080;\"><strong>\u898b\u305b\u304b\u3051\u306e\u52b9\u679c<\/strong><\/span>\u3092\u307f\u3066\u3044\u308b\u3060\u3051\u306a\u306e\u3067\u3059<\/li>\n<li>\u6ce8\u610f\u3057\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u306e\u306f\uff0c\u60a3\u8005\u3055\u3093\u306b\u3088\u3063\u3066\u306f\uff0c\u540c\u6642\u306bFLAIR \u30d5\u30ec\u30a2\u753b\u50cf\u3067\u306e\uff0c\u9ad8\u4fe1\u53f7\u75c5\u5909\uff08\u767d\u304f\u306b\u3058\u3080\u9818\u57df\uff09\u304c\u305d\u306e\u5468\u56f2\u306b\u62e1\u5927\u3057\u3066\u304f\u308b\u3053\u3068\u3067\u3059<\/li>\n<li>\u30b0\u30ea\u30aa\u30de\u30c8\u30fc\u30b7\u30b9 \u795e\u7d4c\u81a0\u816b\u75c7\u306e\u3088\u3046\u306a\u753b\u50cf\u3078\u5909\u5316\u3057\u3066\u304f\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n<li>\u3053\u308c\u306f\u661f\u7d30\u80de\u7cfb\u816b\u760d\u3068\u4e4f\u7a81\u8d77\u81a0\u7d30\u80de\u7cfb\u816b\u760d\u306b\u307f\u3089\u308c\u308b\u73fe\u8c61\u3067\u3059\u304c\uff0c\u816b\u760d\u306e\u6d78\u6f64\u7bc4\u56f2\u304c\u5e83\u304c\u3063\u3066\u3044\u308b\u3053\u3068\u3092\u793a\u3057\u307e\u3059\u3002<\/li>\n<li>\u3053\u308c\u306f\u5358\u306b\u816b\u760d\u304c\u9032\u884c\u75c5\u5909\u3068\u306a\u3063\u3066\u3044\u308b\u304b\u3089\u3067\u3059\u3057\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u306e\u305f\u3081\u306b\u60aa\u5316\u3057\u3066\u3044\u308b\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/li>\n<\/ul>\n<div>\n<h4><span style=\"color: #ff0000;\"><strong>\u653e\u5c04\u7dda\u58ca\u6b7b\u306e\u6cbb\u7642\u306b\u4f7f\u3048\u307e\u3059\uff08\u91cd\u8981\uff09<\/strong><\/span><\/h4>\n<p>Gonzalez J, et al.: Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiation Oncology Biol. Phys 67: 323\u2013326, 2007<br \/>\n2007\u5e74\u306e\u753b\u671f\u7684\u306a\u5831\u544a\u3067\u3057\u305f\uff0c\u653e\u5c04\u7dda\u58ca\u6b7b\u306e\u7d44\u7e54\u5185\u3067VEGF\u304c\u7523\u751f\u3055\u308c\u308b\u305f\u3081\u306b\uff0c\u7d30\u8840\u7ba1\u304b\u3089\u306e\u8840\u6db2\u6f3f\u6db2\u6027\u5206\u304c\u6f0f\u51fa\u3059\u308b\u3068\u3044\u3046\u3053\u3068\u306b\u7740\u76ee\u3057\u3066\uff0cVEGF\u306e\u50cd\u304d\u3092\u6291\u3048\u308b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u6295\u4e0e\u3057\u307e\u3057\u305f\u3002\u653e\u5c04\u7dda\u58ca\u6b7b\u304c\u3042\u308b8\u4eba\u306e\u60a3\u8005\u3055\u3093\u306b\u6295\u4e0e\u304c\u884c\u306a\u308f\u308c\u5168\u54e1\u306b\u6709\u52b9\u6027\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u6295\u4e0e\u5f8c\u304a\u3088\u305d8\u9031\u9593\u3067\uff0cFLAIR\u753b\u50cf\u3067\u306e\u8840\u7ba1\u539f\u6027\u8133\u6d6e\u816b\u306e\u7e2e\u5c0f\uff0c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u753b\u50cf\u3067\u306e\u9020\u5f71\u5264\u6f0f\u51fa\u90e8\u5206\u306e\u7e2e\u5c0f\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f\u3002\u3057\u304b\u3057\uff0c\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\uff0c\u80ba\u585e\u6813\u306a\u3069\u306e\u526f\u4f5c\u7528\u3084\u9ad8\u984d\u306a\u533b\u7642\u8cbb\u306a\u3069\u306e\u554f\u984c\u304b\u3089\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u306b\u614e\u91cd\u306a\u5831\u544a\u3082\u76f8\u6b21\u3044\u3067\u3044\u307e\u3059\u3002<\/p>\n<p>Levin VA, et al .: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79: 1487-1495, 2011<br \/>\n\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u3067\u306f\u306a\u3044\u653e\u5c04\u7dda\u58ca\u6b7b\u306e\u60a3\u8005\u3055\u309314\u540d\u306b\u7121\u4f5c\u70ba\u8a66\u9a13\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u30022010\u5e74\u306eDr. \u3053\u306e\u5831\u544a\u3067\u306f\uff0cbevacizumab at a dose of 7.5 mg\/kg at 3-week intervals for two to four treatments\u3068\u8a18\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\u30027\u4eba\u306e\u30d7\u30e9\u30bb\u30dc\uff08\u507d\u85ac\uff09\u6295\u4e0e\u3092\u3055\u308c\u305f\u60a3\u8005\u3055\u3093\u3067\u306f\u5168\u304f\u6539\u5584\u304c\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u304c\uff0c<span style=\"color: #000080;\"><strong>\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u6295\u4e0e\u3055\u308c\u305f\u60a3\u8005\u3055\u3093\u5168\u54e1\u3067MRI\u3067\u306e\u6539\u5584\u6240\u898b\u304c\u3042\u308a\u81e8\u5e8a\u75c7\u72b6\u3082\u6539\u5584<\/strong><\/span>\u3057\u307e\u3057\u305f\u3002\u4e2d\u592e\u5024\u3067<strong><span style=\"color: #000080;\">10\u30f6\u6708\u9593\u306e\u6295\u4e0e<\/span><\/strong>\u304c\u306a\u3055\u308c\u307e\u3057\u305f\u3002\u653e\u5c04\u7dda\u58ca\u6b7b\u306e\u518d\u71c3\u306f2\u4eba\u306e\u60a3\u8005\u3055\u3093\u306b\u751f\u3058\u3066\uff0c\uff12\u4eba\u3068\u3082\u307e\u305f\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u304c\u306a\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u306e\u7d50\u679c\u306fClass I evidence\u3067\u3042\u308b\u3068\u7d50\u8ad6\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3069\u306e\u7a0b\u5ea6\u306e\u85ac\u5264\u91cf\u3092\u3069\u306e\u7a0b\u5ea6\u306e\u671f\u9593\u306b\u308f\u305f\u3063\u3066\u6295\u4e0e\u3059\u308b\u3079\u304d\u304b\u306f\u306f\u3063\u304d\u308a\u3057\u3066\u3044\u307e\u305b\u3093\u3002\u3067\u3082\u653e\u5c04\u7dda\u58ca\u6b7b\u306e\u671f\u9593\u306f\u9577\u3044\u306e\u30671\u5e74\u304f\u3089\u3044\u306e\u6295\u4e0e\u3092\u3057\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u306e\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002<\/p>\n<h4>\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u4fdd\u967a\u8a3a\u7642\u306f2013\u5e746\u6708\u306b\u627f\u8a8d\u3055\u308c\u307e\u3057\u305f<\/h4>\n<p>\u6fa4\u6751\u3082\u65e5\u672c\u3067\u6700\u521d\u306e\u6cbb\u9a13\u306b\u53c2\u52a0\u3057\u307e\u3057\u305f\u3002<strong><br \/>\n<\/strong>\u521d\u767a\u3067\u3082\u518d\u767a\u3067\u3082\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u3067\u3042\u308c\u3070\u4fdd\u967a\u8a3a\u7642\u3067\u4f7f\u7528\u304c\u3067\u304d\u307e\u3059\u3002\u533b\u5e2b\u3084\u770b\u8b77\u5e2b\u306a\u3069\u304c\u3053\u306e\u85ac\u5264\u306e\u4f7f\u7528\u306b\u95a2\u3057\u3066\u5341\u5206\u306a\u77e5\u8b58\u3092\u6709\u3059\u308b\u3053\u3068\u3082\u6761\u4ef6\u3068\u306a\u308a\u307e\u3059\u3002\u4fdd\u967a\u8a3a\u7642\u304c\u8a8d\u3081\u3089\u308c\u3066\u3082\u85ac\u5264\u8cbb\u3060\u3051\u3067\u6708\u306b\u6570\u5341\u4e07\u5186\u3067\u3059\u304b\u3089\uff0c\u9ad8\u984d\u533b\u7642\u8cbb\u306e\u5bfe\u8c61\u3068\u306a\u308a\u307e\u3059\u3002\u81ea\u5df1\u8ca0\u62c5\u984d\u306f\u60a3\u8005\u3055\u3093\u306e\u5e74\u53ce\u306b\u3088\u3063\u3066\u9055\u3044\u307e\u3059\u304c\uff0c\u901a\u5e38\u306e\u53ce\u5165\u304c\u3042\u308b\u4e00\u822c\u7684\u306a3\u5272\u8ca0\u62c5\u306e\u60a3\u8005\u3055\u3093\u3067\uff0c\u5916\u6765\u3067\u306f\u6bce\u67088\u4e07\u304b\u308910\u4e07\u5186\u5f31\u8fd1\u3044\u8ca0\u62c5\u3068\u306a\u308b\u3068\u8003\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/p>\n<\/div>\n<h5><span style=\"color: #000080;\">\u4e3b\u306a\u5831\u544a<\/span><\/h5>\n<h4>\u518d\u767a\u81a0\u82bd\u816b\u3067\u3082\u30a2\u30d0\u30b9\u30c1\u30f3\u6709\u52b9\u4f8b\u306f\u3042\u308b<\/h4>\n<p>Morisse MC: Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.\u00a0<span role=\"menubar\">J Neurooncol.<\/span> 2019<br \/>\n814\u4f8b\u306e\u518d\u767a\u81a0\u82bd\u816b\u306e\u89e3\u6790\u3067\u3059\u3002secondary GBM\u3068\u30a2\u30d0\u30b9\u30c1\u30f3\u6295\u4e0e\u65e2\u5f80\u4f8b\u306f\u9664\u5916\u3055\u308c\u307e\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u6295\u4e0e\u958b\u59cb\u304b\u308912\u30f6\u6708\u5f8c\u307e\u3067\uff0cRANO criteria\u3067\u9032\u884c\u304c\u306a\u304b\u3063\u305f\u306e\u306f64\u4f8b (LR long responder)\u3067\u3057\u305f\u3002\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f21\u30f6\u6708\uff0c\u5168\u751f\u5b58\u671f\u959331\u30f6\u6708\u3067\u3059\u3002\u304a\u3088\u305d8%\u3067\u30a2\u30d0\u30b9\u30c1\u30f3\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u3068\u3044\u3046\u63a8\u5b9a\u5024\u304c\u3067\u307e\u3059\u3002\u8457\u8005\u306f12\u4eba\u306b\u4e00\u4eba\u304f\u3089\u3044\u306e\u6709\u52b9\u4f8b\u304c\u3042\u308b\u3068\u8a00\u3063\u3066\u3044\u307e\u3059\u3002<br \/>\n\u300c\u89e3\u8aac\u300d\u65e5\u672c\u3067\u306f\u81a0\u82bd\u816b\u306e\u518d\u767a\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u6295\u4e0e\u304c\u4fdd\u967a\u8a3a\u7642\u3067\u8a8d\u3081\u3089\u308c\u3066\u3044\u308b\u306e\u3067\uff0c\u3053\u306e\u6cbb\u7642\u306f\u884c\u308f\u308c\u3066\u3044\u308b\u3067\u3057\u3087\u3046\u3002LR 12\u30f6\u6708\u3068\u3057\u3066\u6709\u52b9\u306a\u306e\u306f8%\u3067\u3059\u304c\uff0c\u9ad8\u984d\u306a\u533b\u7642\u8cbb\u304c\u305d\u308c\u306b\u307f\u3042\u3046\u304b\u3069\u3046\u304b\u306e\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u5206\u6790\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/p>\n<h4>\u9ad8\u9f62\u8005\u306e\u77ed\u671f\u9593\u653e\u5c04\u7dda\u6cbb\u7642\u3068\u4f75\u7528\u3057\u3066\u3082\u52b9\u679c\u306f\u306a\u3044<\/h4>\n<p>Wirsching HG. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol. 2018<br \/>\n\u9ad8\u9f62\u8005\u306e\u81a0\u82bd\u816b\u306b45\u30b0\u30ec\u30a415\u5206\u5272\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u3068\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u7d44\u307f\u5408\u308f\u305b\u305f\u6cbb\u7642\u3067\u3059\u3002\u3084\u306f\u308a\u3068\u3044\u3046\u304b\uff0c\u5168\u751f\u5b58\u671f\u9593\u306f12\u30f6\u6708\u307b\u3069\u3068\u77ed\u304f\uff0c\u5ef6\u9577\u52b9\u679c\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<h4>\u5c0f\u5150\u306e\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u306f\u5ef6\u9577\u3055\u308c\u306a\u3044<\/h4>\n<p>Grill J, et al.: Phase\u00a0II,\u00a0Open-Label,\u00a0Randomized,\u00a0Multicenter\u00a0Trial\u00a0(HERBY) of\u00a0Bevacizumab\u00a0in\u00a0PediatricPatients\u00a0With\u00a0Newly\u00a0Diagnosed\u00a0High-Grade\u00a0Glioma. J Clin Oncol.\u00a02018<br \/>\n3\u6b73\u304b\u308918\u6b73\u306e\u5c0f\u5150121\u4eba\u3067\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u3068\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u306e\u6cbb\u7642\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u52a0\u3048\u308b\u52b9\u679c\u304c\u8a66\u3055\u308c\u307e\u3057\u305f\u3002\u653e\u5c04\u7dda\u3068\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u3067\u306eEFS\uff08\u7121\u5897\u60aa\uff0c\u7121\u30a4\u30d9\u30f3\u30c8\u751f\u5b58\u671f\u9593\uff09\u306f11.8\u30f6\u6708\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4e0a\u4e57\u305b\u3059\u308b\u30688.2\u30f6\u6708\u3067\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u52a0\u3048\u305f\u65b9\u304c\u60aa\u304f\u306a\u308b\u3088\u3046\u306a\u7d50\u679c\u3067\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u52a0\u3048\u3066\u305f\u65b9\u304c\u6709\u5bb3\u4e8b\u8c61\uff08\u526f\u4f5c\u7528\uff09\u306e\u7387\u304c\u9ad8\u3044\u3068\u306e\u3053\u3068\u3067\u3059\u3002<\/p>\n<h4>\u518d\u767a\u7a2e\u81a0\u82bd\u816b\u306b\u30ed\u30e0\u30b9\u30c1\u30f3\u3068\u4f75\u7528\u3059\u308b\u3068\u308f\u305a\u304b\u306a\u304c\u3089PFS\u306e\u5ef6\u9577\u304c\u3042\u308b<\/h4>\n<p>Wick W<span style=\"font-size: small;\">, et al.:<\/span>\u00a0Lomustine and Bevacizumab in Progressive Glioblastoma.\u00a0N Engl J Med.\u00a02017<br \/>\nPhase III EORTC 26101\u306e\u7d50\u679c\u5831\u544a\u3067\u3059\u3002\u81a0\u82bd\u816b\u306e\u518d\u767a\u306b\u30ed\u30e0\u30b9\u30c1\u30f3 CCNU\u5358\u72ec\u3068\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u4f75\u7528\u304c\u8a66\u9a13\u3055\u308c\u307e\u3057\u305f\u3002\u30ed\u30e0\u30b9\u30c1\u30f3\u5358\u72ec\u306ePFS\u306f1.5\u30f6\u6708\uff0c\u30ed\u30e0\u30b9\u30c1\u30f3\u3068\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3059\u308b\u30684.2\u30f6\u6708\u3068\u3044\u3046\u7d50\u679c\u3067\u3059\u3002<br \/>\n\u308f\u305a\u304b\u306a\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u304c\u3042\u308a\u307e\u3059\u3002\u3053\u308c\u306fCCNU\u3068\u306e\u4f75\u7528\u306e\u8a66\u9a13\u306a\u306e\u3067\uff0c\u65e5\u672c\u3067\u306f\u3067\u304d\u306a\u3044\u6cbb\u7642\u3067\u3059\u3002<\/p>\n<h4>IDH-1\u306e\u5909\u7570\u306e\u306a\u3044\u81a0\u82bd\u816b\u306b\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6709\u52b9\u6027\u304c\u3042\u308b<\/h4>\n<p>Sandmann, T, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial.\u00a0<i>J Clin Oncol.\u00a0<\/i>2015<br \/>\n\u81a0\u82bd\u816b\u3092\u9593\u8449\u7cfb (mesenchymal type)\u3068\u524d\u795e\u7d4c (proneural type)\u306b\u5206\u3051\u305f\u5834\u5408\uff0c<span class=\"highlight\">proneural<\/span>\u00a0IDH1 wild-type\u306e\u521d\u671f\u6cbb\u7642\u3067\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4f7f\u7528\u3059\u308b\u3068\u5168\u751f\u5b58\u671f\u9593 OS \u304c\u5ef6\u9577\u3059\u308b\u00a0(17.1\u30f6\u6708 vs \u30d7\u30e9\u30bb\u30dc 12.8\u30f6\u6708) \u3068\u3044\u3046\u7d50\u679c\u3067\u3059\u3002\u50c5\u304b\u306a\u5dee\u306a\u306e\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u304c\u3002<\/p>\n<h4>\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u304c\u52b9\u304b\u306a\u3044\u81a0\u82bd\u816b\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\uff1f<\/h4>\n<p>Herrlinger U, et al.: Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016<br \/>\n\u30e8\u30fc\u30ed\u30c3\u30d1\u304b\u3089\u306e\u5831\u544a\u3067\u3059\u3002MGMT\u975e\u30e1\u30c1\u30eb\u5316\u306e\u81a0\u82bd\u816b\u306f\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u306b\u62b5\u6297\u6027\u3067\u3042\u308b\u4e8b\u304c\u77e5\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u305d\u306e\u3088\u3046\u306a\u60a3\u8005\u3055\u3093182\u4eba\u3067\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u00a0(10 mg\/kg every 2 weeks)\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u4f75\u7528\u00a0(\u7dad\u6301\u7642\u6cd5 125 mg\/m2\u00a0every 2 weeks)\u00a0\u3068\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u3042\u308b\u3044\u306f\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u3068\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u6cbb\u7642\u6210\u7e3e\u304c\u6bd4\u8f03\u3055\u308c\u307e\u3057\u305f\u30026\u30f6\u6708\u7121\u5897\u60aa\u751f\u5b58\u5272\u5408PFS\u306f\u305d\u308c\u305e\u308c79%\u306843%\u3067\u3057\u305f\u3002PFS\u4e2d\u592e\u5024\u306f\uff0c9.7\u30f6\u6708\u30686.0\u30f6\u6708\u3067\u3059\u3002<span style=\"color: #000080;\"><strong>MGMT\u306e\u30e1\u30c1\u30eb\u5316\u304c\u306a\u3044\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u62b5\u6297\u6027\u306e\u81a0\u82bd\u816b\u306b\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u306e\u7d44\u307f\u5408\u308f\u305b\u306e\u65b9\u304c\u816b\u760d\u9032\u884c\u3092\u6291\u5236\u3059\u308b\u529b\u304c\u5f37\u3044<\/strong><\/span>\u3068\u3044\u3046\u5831\u544a\u3067\u3059\u3002\u3057\u304b\u3057\u3084\u306f\u308a\uff0c<strong><span style=\"color: #ff0000;\">\u5168\u751f\u5b58\u5272\u5408\u306f16.6\u30f6\u6708\u306817.5\u30f6\u6708\u3067\u3042\u308a\u6709\u610f\u5dee\u304c\u3042\u308a\u307e\u305b\u3093<\/span><\/strong>\u3067\u3057\u305f\u3002\u307e\u305fQOL\u3092\u5909\u3048\u308b\u3053\u3068\u3082\u3067\u304d\u307e\u305b\u3093\u3067\u3057\u305f\u3002MGMT\u975e\u30e1\u30c1\u30eb\u5316\u3092\u8a3c\u660e\u3057\u3066\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u3092\u4f7f\u7528\u3057\u3066\u3082\u5ef6\u547d\u306f\u3067\u304d\u306a\u3044\u3057\u751f\u5b58\u306e\u8cea\u3082\u6539\u5584\u3057\u306a\u3044\u3068\u3044\u3046\u3053\u3068\u3067\u3059\u3002<\/p>\n<h4>\u518d\u767a\u81a0\u82bd\u816b\u3078\u306e\u52b9\u679c<\/h4>\n<p>Friedman HS, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740, 2009<\/p>\n<p>2009\u5e74Friedman\u3089\u306b\u3088\u3063\u3066\uff0c\u518d\u767a\u306e\u81a0\u82bd\u816b\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u5358\u72ec\u3067\u4f7f\u7528\u3057\u305f\u5834\u5408\u306b\uff0c6\u30f6\u6708\u7121\u5897\u60aa\u751f\u5b58\u5272\u5408\u304c42.6%\u3067\u3042\u308b\u3068\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u308c\u306f\uff0c\u76f4\u63a5\u7684\u306a\u816b\u760d\u5897\u6b96\u6291\u5236\u306e\u307f\u306a\u3089\u305a\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u306epseudoprogression\u306e\u6539\u5584\u3068\u3044\u3046\u753b\u50cf\u6240\u898b\u3092\u542b\u3093\u3060\u8a55\u4fa1 (pseudoresponse) \u3067\u3057\u3087\u3046\u3057\uff0c\u826f\u3059\u304e\u308b\u6210\u7e3e\u3067\u3059\u3002\u3057\u304b\u3057\uff0c\u518d\u767a\u3057\u305f\u81a0\u82bd\u816b\u306e\u81e8\u5e8a\u7684\u5897\u60aa\u3092\u30a2\u30d0\u30b9\u30c1\u30f3\u304c\u4e00\u5b9a\u671f\u9593\u6291\u3048\u308b\u3068\u3044\u3046\u306e\u306f\u660e\u3089\u304b\u306a\u4e8b\u5b9f\u3068\u306a\u308a\u307e\u3057\u305f\u3002<br \/>\n\u305d\u306e\u5f8c\u306e\u5831\u544a\u3092\u9451\u307f\u3066\uff0c\u60a3\u8005\u3055\u3093\u5074\u304b\u3089\u306f\u518d\u767a\u306e\u81a0\u82bd\u816b\u306b\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u5358\u72ec\u3067\u4f7f\u7528\u3057\u305f\u5834\u5408\u306b\u306f\uff0c4\u5272\u304f\u3089\u3044\u306e\u78ba\u7387\uff084\/10\u304f\u3089\u3044\u306e\u60a3\u8005\u3055\u3093\uff09\u3067\u6570\u30f6\u6708\u9593\u306f\u9032\u884c\u3092\u6291\u5236\u3067\u304d\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u3068\u8003\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/p>\n<h4>\u518d\u767a\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u3078\u306e\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u52b9\u679c<\/h4>\n<p>Nghlemphu PL, et al.: Bebacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72: 1217-1222, 2009<br \/>\nNorden AD, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology 70: 779\u2013787, 2008<\/p>\n<p>\u4e21\u8005\u3068\u3082\u3042\u307e\u308a\u91cd\u8981\u306a\u8ad6\u6587\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u304c\uff0c\u6709\u5bb3\u4e8b\u8c61\u304c\u5c11\u306a\u3044\u3053\u3068\u3068\u9ad8\u9f62\u8005\u3067\u306eVEGF\u306e\u767a\u73fe\u304c\u9ad8\u3044\u3053\u3068\u304b\u3089\uff0c\u9ad8\u9f62\u8005\u306b\u6709\u7528\u6027\u304c\u3042\u308b\u3068\u66f8\u304b\u308c\u3066\u3044\u307e\u3059\u3002\u518d\u767a\u30b0\u30ec\u30fc\u30c9\uff13\u3092\u542b\u3081\u308c\u3070\uff17\u5272\u304f\u3089\u3044\u306e\u60a3\u8005\u3055\u3093\u306b\u7e2e\u5c0f\u52b9\u679c\uff08\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u90e8\u5206\uff09\u304c\u3042\u3063\u305f\u3068\u3055\u308c\uff0c\u518d\u767a\u81a0\u82bd\u816b\u3067\u306e\uff16\u30f6\u6708\u7121\u5897\u60aa\u751f\u5b58\u5272\u5408\u306f42%\u3068\u3044\u3046\u9ad8\u3044\u6570\u5b57\u304c\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u304c\u8840\u7ba1\u65b0\u751f\u3092\u6291\u5236\u3059\u308b\u306e\u3067\uff0c\u816b\u760d\u306f\u8840\u7ba1\u304c\u8c4a\u304b\u306a\u584a\u3068\u3057\u3066\u80b2\u3061\u307e\u305b\u3093\u304b\u3089\uff0c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u3067\u5897\u5f37\u3055\u308c\u308b\u816b\u760d\u306f\u5c0f\u3055\u304f\u306a\u308a\u307e\u3059\u3002\u305d\u306e\u304b\u308f\u308a\u4e00\u65b9\u3067\uff0cFLAIR\u753b\u50cf\u3067\u308f\u304b\u308b\u3088\u3046\u306b\uff0c\u5468\u56f2\u306b\u3057\u307f\u8fbc\u3080\u3088\u3046\u306b\u6d78\u6f64\u3057\u3066\u5e83\u304c\u3063\u3066\u3044\u304d\u307e\u3059 (infiltrative tumor growth) \u3002\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u3055\u308c\u308b\u90e8\u5206\u304c\u591a\u3044\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306b\u6709\u52b9\u306a\u306e\u3067\u3057\u3087\u3046\u3002 \u3067\u3059\u304b\u3089\uff0c\u3053\u306e\u6cbb\u7642\u3067\u306f1990\u5e74\u304b\u3089\u6c4e\u7528\u3055\u308c\u3066\u3044\u308bMacdonald criteria\u304c\u4f7f\u7528\u3067\u304d\u307e\u305b\u3093\u3002<br \/>\nDr. Chamberlain\u304c\u307e\u305f\u8ad6\u8a55\u3057\u3066\u3044\u307e\u3059\u3002\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u306f\uff0c\u85ac\u4fa1\u304c\u9ad8\u984d\u3067\u3042\u308a\uff0c\u526f\u4f5c\u7528\u3082\u3042\u308b\u3057\uff0c\u9650\u3089\u308c\u305f\u30bf\u30a4\u30d7\u306b\u3057\u304b\u52b9\u304b\u306a\u3044\u3053\u3068\u306f\u660e\u3089\u304b\u306a\u306e\u3067\uff0cpredictive marker\uff08\u6709\u52b9\u6027\u306e\u78ba\u8a8d\u3067\u304d\u308b\u56e0\u5b50\uff09\u3092\u8abf\u3079\u3066\u304b\u3089\u4f7f\u7528\u3059\u308b\u3079\u304d\u3067\u3042\u308b\u3068\u5f37\u8abf\u3057\u3066\u3044\u307e\u3059\u3002\u5897\u5f37\u3055\u308c\u306a\u3044\u6d78\u6f64\u6027\u306e\u90e8\u5206\u306e\u816b\u760d\u306e\u4f38\u5c55\u3092\u4fc3\u3059\u306e\u3067\u306f\u306a\u3044\u304b\u3068\u306e\u8b66\u544a\u3082\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u3044\u308f\u3086\u308b\u30b0\u30ea\u30aa\u30de\u30c8\u30fc\u30b7\u30b9\u306e\u3088\u3046\u306a\u816b\u760d\u5897\u5927\u3092\u8a98\u767a\u3059\u308b\u3068\u3044\u3046\u306e\u3067\u3059\u3002\u307e\u305f\u30a2\u30d0\u30b9\u30c1\u30f3\u3092\u4e2d\u6b62\u3059\u308b\u3068\u30ea\u30d0\u30a6\u30f3\u30c9\uff08\u6025\u901f\u306a\u518d\u5897\u5927\uff09\u304c\u3042\u308b\u306e\u3067\u9577\u671f\u9593\u6295\u4e0e\u304c\u5fc5\u8981\u3067\u3042\u308b\u3053\u3068\u3082\u6307\u6458\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<h4><strong>\u30a2\u30d0\u30b9\u30c1\u30f3\u3067\u306f\u30b0\u30ea\u30aa\u30fc\u30de\u3092\u6cbb\u305b\u306a\u3044? \u3042\u308b\u3044\u306f\u9006\u52b9\u679c\u3067\u5e83\u304c\u3063\u3066\u3057\u307e\u3046\uff1f<\/strong><\/h4>\n<p align=\"left\">Thompson EM, et al.: The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76: 87\u201393, 2011<br \/>\n<strong><span style=\"color: #ff0000;\">\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u52b9\u679c\u3092\u904e\u5927\u8a55\u4fa1\u3057\u306a\u3044\u3088\u3046\u306b\u3068\u306e\u8b66\u544a\u3067\u3059\u3002<\/span><\/strong><br \/>\n\u30a2\u30d0\u30b9\u30c1\u30f3\u306f\u653e\u5c04\u7dda\u5316\u5b66\u7642\u6cd5\u306e\u52b9\u679c\u3092\u6e1b\u3058\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3068\u3044\u3046\u3053\u3068\u306a\u3069\u304c\u66f8\u304b\u308c\u3066\u3044\u307e\u3059\u3002\u816b\u760d\u8840\u7ba1\u3092\u6b63\u5e38\u5316\u3059\u308b\u3053\u3068\u3067\u6297\u304c\u3093\u5264\u306e\u5230\u9054\u304c\u60aa\u304f\u306a\u3063\u3066\uff0c\u816b\u760d\u7d30\u80de\u3092\u6bba\u3059\u529b cytocydal effect \u306e\u3042\u308b\u6297\u304c\u3093\u5264\u306e\u816b\u760d\u5185\u3078\u306e\u5230\u9054\u304c\u4f4e\u4e0b\u3059\u308b\u3068\u3044\u3046\u7406\u8ad6\u3067\u3059\u3002\u307e\u305f\u816b\u760d\u7d30\u80de\u306e\u6027\u8cea phenotype \u304c\u5909\u5316\u3057\u3066\u6d78\u6f64\u80fd\u304c\u9ad8\u307e\u308a\uff0c\u816b\u760d\u304c\u5e83\u7bc4\u56f2\u306b\u5e83\u304c\u308b\u53ef\u80fd\u6027\u3082\u3042\u308b\u3068\u306e\u3053\u3068\u3067\u3059\u3002<br \/>\n\u3042\u308b\u52d5\u7269\u5b9f\u9a13\u3067\u306f\uff0c\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u4e3b\u306a\u52b9\u679c\u306f\u816b\u760d\u306b\u3088\u308b\u7d44\u7e54\u6d6e\u816b\u3092\u6e1b\u3089\u3059\u3053\u3068\u3067\u3042\u3063\u3066\uff0c\u305d\u308c\u306b\u3088\u3063\u3066\u5b9f\u9a13\u52d5\u7269\u306f\u9577\u751f\u304d\u3059\u308b\u3051\u308c\u3069\u3082\uff0c\u816b\u760d\u4f53\u7a4d\u81ea\u4f53\u306f\u7e2e\u5c0f\u305b\u305a\u306b\u5927\u304d\u304f\u306a\u3063\u3066\u3044\u308b\u3068\u3044\u3046\u3053\u3068\u3082\u6307\u6458\u3057\u3066\u3044\u307e\u3059 (Jahnke K, Neuro-Oncol\u00a02009)\u3002<br \/>\n\u540c\u69d8\u306b\u6700\u8fd1\u306e\u81e8\u5e8a\u7814\u7a76\u3067\u3082\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u306f\u5ef6\u9577\u3055\u308c\u308b\u306e\u3067\u3059\u304c\uff0c\u5168\u751f\u5b58\u671f\u9593\u306f\u5ef6\u3073\u306a\u3044\u3053\u3068\u304c\u6307\u6458\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3082\u3063\u3068\u5177\u4f53\u7684\u306b\u306f\uff0c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u3055\u308c\u308b\u90e8\u5206\u306e\u816b\u760d\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6295\u4e0e\u3067\u7e2e\u5c0f\u3059\u308b\u306e\u3067\u3059\u304c\uff0cFLAIR\u753b\u50cf\u3067\u63cf\u51fa\u3055\u308c\u308b\u6d78\u6f64\u816b\u760d\u306e\u5e83\u304c\u308a\u306f\u30a2\u30d0\u30b9\u30c1\u30f3\u6295\u4e0e\u3067\u9006\u306b\u5897\u5927\u3057\u3066\u3057\u307e\u3046\u304b\u3082\u3057\u308c\u306a\u3044\u3068\u3044\u3046\u6307\u6458\u3067\u3059\u3002\u307e\u305f\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u75c5\u5909\u306e\u6d88\u9577\u3067\u52b9\u679c\u3092\u5224\u5b9a\u3059\u308bMacdonald criteria\u3068\u3044\u3046\u65b9\u6cd5\u3067\u6cbb\u7642\u52b9\u679c\u3092\u5224\u5b9a\u3057\u3066\u306f\u3044\u3051\u306a\u3044\u3068\u5f37\u8abf\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<h5 align=\"left\"><\/h5>\n<p><a href=\"\/sawamura\/wp\/wp-content\/uploads\/2013\/01\/owlwing.jpg\" rel=\"attachment wp-att-8620\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-8620\" src=\"\/sawamura\/wp\/wp-content\/uploads\/2013\/01\/owlwing-472x600.jpg\" alt=\"owlwing\" width=\"472\" height=\"600\" srcset=\"https:\/\/plaza.umin.ac.jp\/sawamura\/wp\/wp-content\/uploads\/2013\/01\/owlwing-472x600.jpg 472w, https:\/\/plaza.umin.ac.jp\/sawamura\/wp\/wp-content\/uploads\/2013\/01\/owlwing-236x300.jpg 236w, https:\/\/plaza.umin.ac.jp\/sawamura\/wp\/wp-content\/uploads\/2013\/01\/owlwing.jpg 532w\" sizes=\"auto, (max-width: 472px) 100vw, 472px\" \/><\/a><\/p>\n<h5 align=\"left\">\u6587\u732e<\/h5>\n<ul>\n<li>Bokstein F, et al.: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112: 2267-2273, 2008<\/li>\n<li>Chamberlain NC, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:1012; author reply 1013, 2008<\/li>\n<li>Chinot OL, et al.: Bebacizmab plus radiotherapy-temozolomide for newly diagnosed gliomblastoma. N Engl J Med 370: 709-722, 2014<\/li>\n<li>Friedman HS, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009<\/li>\n<li>Gilbert MR, et al.: A randomized trial of bevacizmab for newly diagnosed glioblastoma.\u00a0 N Engl J Med 370: 699-708, 2014<\/li>\n<li>Grill J, et al.: Phase\u00a0II,\u00a0Open-Label,\u00a0Randomized,\u00a0Multicenter\u00a0Trial\u00a0(HERBY) of\u00a0Bevacizumab\u00a0in\u00a0PediatricPatients\u00a0With\u00a0Newly\u00a0Diagnosed\u00a0High-Grade\u00a0Glioma. J Clin Oncol.\u00a02018<\/li>\n<li>Gonzalez J, et al.: Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiation Oncology Biol. Phys 67: 323\u2013326, 2007<\/li>\n<li>Herringer U, et al.: Bevasizumab, Irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients; Updated results from the randomized multi center GLARIUS trial. ECCO-ESMO-ESTRO 2013<\/li>\n<li>Herrlinger U, et al.: Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016 [Epub]<\/li>\n<li>Lai A, et al.: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148, 2011<\/li>\n<li>Levin VA, et al .: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79: 1487-1495, 2011<\/li>\n<li>Nghlemphu PL, et al.: Bebacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72: 1217-1222, 2009<br \/>\nNorden AD, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology 70: 779\u2013787, 2008<\/li>\n<li>Sathornsumetee S, et al.: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278, 2008<\/li>\n<li>Thompson EM, et al.: The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76: 87\u201393, 2011<\/li>\n<li>Vredenburgh JJ, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007<\/li>\n<\/ul>\n<h5 align=\"left\">\u3061\u3087\u3063\u3068\u4f59\u5206\u306a\u77e5\u8b58<\/h5>\n<h4><strong>\u30a2\u30d0\u30b9\u30c1\u30f3\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3<\/strong><\/h4>\n<p>\u4eca\u307e\u3067\u306b\uff0c\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\uff08\u30a2\u30d0\u30b9\u30c1\u30f3, Bevacizumab)\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3(CPT-11)\u306e\u4f75\u7528\u306e\u8ad6\u6587\u304c\u305f\u304f\u3055\u3093\u51fa\u307e\u3057\u305f\u3002\u3067\u30822016\u5e74\u306b\u306f\u305d\u306e\u52b9\u679c\u306f\u5426\u5b9a\u3055\u308c\u307e\u3057\u305f\u3002<strong><br \/>\n<\/strong><\/p>\n<p align=\"left\">Friedman HS, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009<br \/>\n165\u4eba\u306e\u518d\u767a\u81a0\u82bd\u816b\u60a3\u8005\u3055\u3093\u306b\uff0c\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\uff08\u30a2\u30d0\u30b9\u30c1\u30f3\uff0910mg\/kg\u5358\u72ec\uff0c\u3042\u308b\u3044\u306f\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3 125-340mg\/m2\u306e\u6295\u4e0e\u304c\u306a\u3055\u308c\u307e\u3057\u305f\u30026\u30f6\u6708\u7121\u5897\u60aa\u751f\u5b58\u5272\u5408\u306f\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u5358\u72ec\u306742.6%\uff0c\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u3068\u306e\u4f75\u7528\u306750.3%\u3067\u3057\u305f\u3002\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f\uff0c\u305d\u308c\u305e\u308c9.2\u30f6\u6708\u30688.7\u30f6\u6708\u3067\u3059\u3002<\/p>\n<p align=\"left\">Bokstein F, et al.: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112: 2267-2273, 2008<br \/>\n19\u4eba\u306e\u518d\u767a\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u60a3\u8005\u3055\u3093\u306b\uff0c\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\uff08\u30a2\u30d0\u30b9\u30c1\u30f3\uff095mg\/kg\u3068\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3125mg\/m2\u304c\uff12\u9031\u9593\u9593\u9694\u3067\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\uff12\u4eba\u306e\u60a3\u8005\u3055\u3093\u3067\u816b\u760d\u304c\u6d88\u3048\u3066(CR)\uff0c\uff17\u4eba\u306e\u60a3\u8005\u3055\u3093\u3067\u816b\u760d\u304c\u304b\u306a\u308a\u5c0f\u3055\u304f\u306a\u308a\u307e\u3057\u305f(PR)\u3002\u594f\u529f\u7387\u306f47%\u306b\u3082\u306a\u308a\u307e\u3059\u3002\u3067\u3082\u4e2d\u592e\u50244.7\u30f6\u6708\u3067\u307e\u305f\u816b\u760d\u306f\u5927\u304d\u304f\u306a\u3063\u305f\u305d\u3046\u3067\u3059\u3002\u51fa\u8840\u3084\u585e\u6813\u306a\u3069\u306e\u3072\u3069\u3044\u5408\u4f75\u75c7\u306f\u306a\u304b\u3063\u305f\u3068\u306e\u3053\u3068\u3067\u3059\u3002\uff16\u30f6\u6708\u6642\u70b9\u3067\u75c5\u6c17\u304c\u9032\u884c\u3057\u306a\u3044\u3067\u751f\u5b58\u3057\u3066\u3044\u305f\u60a3\u8005\u3055\u3093\u306f25%\u3067\u3057\u305f\u3002<\/p>\n<p align=\"left\">Sathornsumetee S, et al.: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278, 2008<br \/>\n45\u4eba\u306e\u518d\u767a\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u60a3\u8005\u3055\u3093\u304c\u7b2c\uff12\u76f8\u8a66\u9a13\u3067\u6cbb\u7642\u3055\u308c\u307e\u3057\u305f\u300227\u4eba\u306f\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u3067\u3059\u300226\u4eba(58%)\u306e\u60a3\u8005\u3055\u3093\u3067\u753b\u50cf\u4e0a\u3067\u306e\u816b\u760d\u306f\u5c0f\u3055\u304f\u306a\u308a\u307e\u3057\u305f\u3002VEGF\u3068\u3044\u3046\u53d7\u5bb9\u4f53\u306e\u767a\u73fe\u304c\u9ad8\u3044\u816b\u760d\u3067\u753b\u50cf\u4e0a\u3067\u306e\u6709\u52b9\u7387\u304c\u9ad8\u304b\u3063\u305f\u3088\u3046\u3067\u3059\u304c\uff0c\u751f\u5b58\u671f\u9593\u3068\u306f\u3042\u307e\u308a\u95a2\u4fc2\u306a\u3044\u3068\u3055\u308c\u307e\u3057\u305f\u3002\u4f4e\u9178\u7d20\u72b6\u614b\u3067\u8a98\u5c0e\u3055\u308c\u308bCA9\u3068\u3044\u3046\u9175\u7d20\u304c\u9ad8\u3044\u816b\u760d\u3067\u306f\u751f\u5b58\u7387\u304c\u4f4e\u304b\u3063\u305f\u3088\u3046\u3067\u3059\u3002<\/p>\n<p align=\"left\">Vredenburgh JJ, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007<br \/>\n\u518d\u767a\u3057\u305f35\u4eba\u306e\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u3067\u3059\u3002\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u306f10\u3042\u308b\u3044\u306f15 mg\/kg\u3067\u4f7f\u7528\u3055\u308c\uff0c\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u3068\u4f75\u7528\u3055\u308c\u307e\u3057\u305f\u3002\uff16\u30f6\u6708\u9593\u9032\u884c\u3057\u306a\u3044\u3067\u751f\u5b58\u3057\u305f\u60a3\u8005\u3055\u3093\u306f46%\u3067\uff0c21\u4eba\u306e\u60a3\u8005\u3055\u3093(57%)\u3067\u304b\u306a\u308a\u816b\u760d\u304c\u5c0f\u3055\u304f\u306a\u3063\u305f\u305d\u3046\u3067\u3059\u3002\uff11\u4eba\u306e\u60a3\u8005\u3055\u3093\u3067\u8133\u51fa\u8840\u304c\u751f\u3058\uff0c\uff14\u4eba\u306e\u60a3\u8005\u3055\u3093\u3067\u80ba\u585e\u6813\u306a\u3069\u304c\u8d77\u3053\u3063\u305f\u305d\u3046\u3067\u3059\u3002<\/p>\n<p align=\"left\">\u89e3\u8aac\u306e\u304b\u308f\u308a\u306b\u3053\u308c\u3092\u8aad\u3093\u3067\u4e0b\u3055\u3044<br \/>\nChamberlain NC, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:1012; author reply 1013, 2008<br \/>\n\u3053\u308c\u306f\u8a55\u8ad6\u7684\u306a\u8ad6\u6587\u3067\u3059\u3002\u307e\u305a\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u304c\u5358\u72ec\u3067\u306f\u518d\u767a\u306e\u81a0\u82bd\u816b\u306b\u52b9\u304b\u306a\u3044\u85ac\u5264\u3067\u3042\u308b\u3068\u3044\u3046\u3053\u3068\u3092\u78ba\u8a8d\u3057\u3066\u3044\u307e\u3059\u3002\u306a\u305c\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u3068\u306e\u4f75\u7528\u3092\u884c\u3063\u305f\u306e\u304b\u306e\u6839\u62e0\u304c\u5e0c\u8584\u3067\u3042\u308b\u3068\u3044\u3063\u3066\u307e\u3059\u3002\u307e\u305f\uff0c\u307e\u3060100\u4eba\u306b\u3082\u6e80\u305f\u306a\u3044\u60a3\u8005\u3055\u3093\u306b\u3053\u306e\u6cbb\u7642\u304c\u8a66\u3055\u308c\u305f\u3068\u3044\u3046\u5831\u544a\u3057\u304b\u306a\u3044\u306e\u306b\uff0c\u60a3\u8005\u3055\u3093\u306e\u3053\u306e\u6cbb\u7642\u306b\u5bfe\u3059\u308b\u8981\u6c42\u304c\u3059\u3067\u306b\u304b\u306a\u308a\u9ad8\u307e\u3063\u3066\u3044\u308b\u305d\u3046\u3067\u3059\u3002\u307e\u305f\u3053\u306e\u6cbb\u7642\u306e\u6599\u91d1\u304c\u3082\u306e\u3059\u3054\u304f\u9ad8\u984d\u3067\u3042\u308b\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u30ef\u30b7\u30f3\u30c8\u30f3\u5927\u5b66\u3067\u306f\u4e00\u56de\u3042\u305f\u308a\u306e\u6295\u4e0e\u306b\uff0c\u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u30674000-9000\u30c9\u30eb\uff0c\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u30679000\u30c9\u30eb\u304b\u304b\u3063\u305f\u305d\u3046\u3067\u3059\u3002\u5f53\u6642\u306e\u65e5\u672c\u5186\u306b\u3059\u308b\u3068\uff11\u30b3\u30fc\u30b9\u306e\u6295\u4e0e\u30671,800,000\u5186\u3067\u3059(\u252f_\u252f)\u3002<strong><span style=\"color: #000080;\">\uff16\u30f6\u6708\u306e\u6295\u4e0e\u3067\u3059\u3068\uff0c169,000-234,000\u30c9\u30eb\uff0c\uff12\u5343\u4e07\u5186\u304f\u3089\u3044<\/span>\u00a0<\/strong>o(^o^)o \u306a\u3093\u3060\u3053\u308a\u3083\uff01\u9ad8\u3059\u304e\u308b\u304b\u3089\u4fdd\u967a\u4f1a\u793e\u304c\u304a\u91d1\u3092\u51fa\u3055\u306a\u3044\u306e\u3067\uff0c\u4fdd\u967a\u306f\u5229\u304b\u306a\u3044\u3057\uff0c\u4f7f\u3048\u308b\u60a3\u8005\u3055\u3093\u304c\u6c7a\u307e\u3063\u3066\u3044\u308b\u6cbb\u7642\u3067\u3059\u3002\u3055\u3089\u306b\u7d9a\u3051\u307e\u3059\uff0c\u8840\u7ba1\u65b0\u751f\u304c\u59a8\u3052\u3089\u308c\u308b\u306e\u3067\uff0c\u958b\u982d\u90e8\u4f4d\u306e\u7834\u7dbb dehiscence \u304c\u751f\u3058\u308b\u3053\u3068\u304c\u5c11\u306a\u304f\u306a\u3044\u3068\u306e\u3053\u3068\u3067\u3059\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u85ac\u30d9\u30d0\u30b7\u30ba\u30de\u30d6 \u00a0bevacizumab \u8133\u5185\u90e8\u304b\u3089\u3067\u308b\u30b0\u30ea\u30aa\u30fc\u30de\uff08\u60aa\u6027\u795e\u7d4c\u81a0\u816b\uff09\u306e\u6cbb\u7642\u306b\u4f7f\u308f\u308c\u308b\u85ac\u3067\u3059 \u81a0\u82bd\u816b\u3068\u304b\u9000\u5f62\u6210\u6027\u661f\u7d30\u80de\u816b\u3068\u304b\u3044\u308d\u3044\u308d\u306a\u60aa\u6027\u8133\u816b\u760d\u306b\u6709\u52b9\u306a\u3053\u3068\u304c\u3042\u308a\u307e\u3059 \u30b0\u30ea\u30aa\u30fc\u30de\u306e\u816b\u760d\u8840\u7ba1\u304c\u5897\u3048\u308b [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-1735","post","type-post","status-publish","format-standard","hentry","category-glioma"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/1735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/comments?post=1735"}],"version-history":[{"count":103,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/1735\/revisions"}],"predecessor-version":[{"id":16696,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/1735\/revisions\/16696"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/media?parent=1735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/categories?post=1735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/tags?post=1735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}